Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder; RLS-01, a formulation of Salvinorin A for TRD; KUR-101, an oral formulation of deuterated mitragynine to treat OUD; and DMX-1001, an oral formulation of noribogaine for the treatment of OUD. The company was formerly known as Adripa Holding B.V. Atai Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.

Atai Life Sciences N.V.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

SOUTH SAN FRANCISCO, JULY 25, 2025 (GLOBE NEWSWIRE) -- RECOGNIFY LIFE SCIENCES, A CLINICAL-STAGE BIOTECH COMPANY FOCUSED ON DEVELOPING TREATMENTS FOR COGNITIVE IMPAIRMENT, TODAY ANNOUNCED THAT ITS RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2B CLINICAL TRIAL EVALUATING INIDASCAMINE (FORMERLY RL-007) IN PATIENTS WITH COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA (CIAS) DID NOT MEET ITS PRIMARY ENDPOINT.

RECOGNIFY LIFE SCIENCES PROVIDES UPDATE ON PHASE 2B TRIAL OF INIDASCAMINE IN PATIENTS WITH COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA

FINANCING CO-LED BY FERRING VENTURES S.A. AND APEIRON INVESTMENT LTD. WITH PARTICIPATION FROM NEW AND EXISTING HEALTHCARE-FOCUSED INSTITUTIONAL INVESTORS, INCLUDING ALLY BRIDGE GROUP AND ADAR1 FINANCING CO-LED BY FERRING VENTURES S.A. AND APEIRON INVESTMENT LTD. WITH PARTICIPATION FROM NEW AND EXISTING HEALTHCARE-FOCUSED INSTITUTIONAL INVESTORS, INCLUDING ALLY BRIDGE GROUP AND ADAR1

ATAI LIFE SCIENCES ANNOUNCES $50 MILLION PRIVATE PLACEMENT FINANCING

NEW YORK, AND AMSTERDAM AND OXFORD, UNITED KINGDOM, JULY 01, 2025 (GLOBE NEWSWIRE) -- ATAI LIFE SCIENCES(NASDAQ: ATAI) (ATAI), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY ON A MISSION TO DEVELOP HIGHLY EFFECTIVE MENTAL HEALTH TREATMENTS TO TRANSFORM PATIENT OUTCOMES, AND BECKLEY PSYTECH LIMITED(BECKLEY PSYTECH), A PRIVATE CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY PIONEERING THE NEXT GENERATION OF MENTAL HEALTH TREATMENTS, TODAY JOINTLY ANNOUNCED POSITIVE TOPLINE RESULTS FROM THE EIGHT-WEEK, QUADRUPLE-MASKED, DOSE-FINDING, CORE STAGE OF THE PHASE 2B CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF A SINGLE DOSE OF BPL-003 (INTRANASAL MEBUFOTENIN (5-MEO-DMT) BENZOATE) IN PATIENTS WITH TREATMENT-RESISTANT DEPRESSION (TRD). THE STUDY ACHIEVED ITS PRIMARY ENDPOINT AS WELL AS ALL KEY SECONDARY ENDPOINTS. AT DAY 29, A SINGLE 12 MG DOSE OF BPL-003 DEMONSTRATED A STATISTICALLY SIGNIFICANT REDUCTION IN DEPRESSIVE SYMPTOMS, AS MEASURED BY THE MONTGOMERY-SBERG DEPRESSION RATING SCALE (MADRS), WITH A MEAN DECREASE OF 11.1 POINTS FROM BASELINE COMPARED TO A 5.8 POINT REDUCTION IN THE 0.3 MG COMPARATOR GROUP (P = 0.0038). FOR THE KEY SECONDARY EFFICACY ENDPOINTS, A SINGLE 8 MG DOSE OF BPL-003 ALSO SHOWED SIGNIFICANT IMPROVEMENT AT DAY 29, WITH A MEAN MADRS SCORE REDUCTION OF 12.1 POINTS (P=0.0025 FOR CHANGE VS. 0.3 MG CONTROL). NOTABLY, BOTH THE 8MG AND 12MG DOSES OF BPL-003 SHOWED STATISTICALLY SIGNIFICANT IMPROVEMENTS IN MADRS SCORES AS EARLY AS ONE DAY AFTER DOSING, WITH EFFECTS GENERALLY MAINTAINED OUT TO WEEK 8.

ATAI LIFE SCIENCES AND BECKLEY PSYTECH ANNOUNCE POSITIVE TOPLINE RESULTS FROM THE PHASE 2B STUDY OF BPL-003 IN PATIENTS WITH TREATMENT-RESISTANT DEPRESSION

NEW YORK AND BERLIN AND OXFORD, UNITED KINGDOM, JUNE 02, 2025 (GLOBE NEWSWIRE) -- ATAI LIFE SCIENCES (NASDAQ: ATAI) (ATAI OR COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY ON A MISSION TO DEVELOP HIGHLY EFFECTIVE MENTAL HEALTH TREATMENTS TO TRANSFORM PATIENT OUTCOMES, AND BECKLEY PSYTECH LIMITED (BECKLEY), A PRIVATE CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY PIONEERING THE NEXT GENERATION OF MENTAL HEALTH TREATMENTS, TODAY ANNOUNCED A DEFINITIVE AGREEMENT UNDER WHICH ATAI AND BECKLEY PLAN TO COMBINE IN AN ALL-SHARE TRANSACTION SUBJECT TO PRE-AGREED BPL-003 (MEBUFOTENIN BENZOATE) PHASE 2B SUCCESS CRITERIA.

ATAI LIFE SCIENCES AND BECKLEY PSYTECH TO COMBINE CREATING A GLOBAL LEADER IN PSYCHEDELIC MENTAL HEALTH THERAPIES

NEW YORK AND BERLIN, MAY 29, 2025 (GLOBE NEWSWIRE) -- ATAI LIFE SCIENCES (NASDAQ: ATAI) (ATAI OR COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY ON A MISSION TO DEVELOP HIGHLY EFFECTIVE MENTAL HEALTH TREATMENTS TO TRANSFORM PATIENT OUTCOMES, TODAY ANNOUNCED THAT THE COMPANY'S MANAGEMENT TEAMIS SCHEDULED TOPARTICIPATE IN THE FOLLOWING INVESTOR CONFERENCES IN JUNE:

ATAI LIFE SCIENCES TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

- POSITIVE RESULTS SHOW THAT A SINGLE DOSE OF BPL-003, ADMINISTERED ADJUNCTIVELY TO SSRIS, PRODUCED A RAPID AND DURABLE ANTIDEPRESSANT EFFECT FOR UP TO THREE MONTHS AFTER DOSING

ATAI LIFE SCIENCES ANNOUNCES POSITIVE TOPLINE DATA FROM PART 2 OF BECKLEY PSYTECH'S PHASE 2A STUDY OF BPL-003 IN COMBINATION WITH SSRIS FOR TREATMENT-RESISTANT DEPRESSION

WITH CLINICAL MOMENTUM ACROSS ITS PIPELINE, ATAI STRENGTHENS ITS POSITION AS A LEADER IN POTENTIALLY TRANSFORMATIVE PSYCHEDELIC MENTAL HEALTH TREATMENTS

ATAI LIFE SCIENCES REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND RECENT CORPORATE UPDATES

- IN A PHASE 1 STUDY, EMP-01 (ORAL R-MDMA) DEMONSTRATED A UNIQUE, DOSE-DEPENDENT SUBJECTIVE EFFECT PROFILE THAT WAS GENERALLY FOUND TO BE MORE SIMILAR TO CLASSICAL PSYCHEDELICS THAN TO RACEMIC MDMA

ATAI LIFE SCIENCES ANNOUNCES FIRST PATIENT DOSED IN PHASE 2 STUDY OF EMP-01 FOR THE TREATMENT OF SOCIAL ANXIETY DISORDER

- ELUMINA IS A PHASE 2, MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, CLINICAL TRIAL TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF VLS-01 (BUCCAL FILM DMT) IN PEOPLE SUFFERING FROM TREATMENT-RESISTANT DEPRESSION

ATAI LIFE SCIENCES ANNOUNCES FIRST PATIENT DOSED IN ELUMINA, THE PHASE 2 CLINICAL TRIAL OF VLS-01 FOR TREATMENT-RESISTANT DEPRESSION

NEW YORK AND BERLIN, FEB. 24, 2025 (GLOBE NEWSWIRE) -- ATAI LIFE SCIENCES (NASDAQ: ATAI) (ATAI OR COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY AIMING TO TRANSFORM THE TREATMENT OF MENTAL HEALTH DISORDERS, TODAY ANNOUNCED THAT THE COMPANY'S MANAGEMENT TEAM IS SCHEDULED TO PARTICIPATE IN THE TD COWEN 45TH ANNUAL HEALTH CARE CONFERENCE IN BOSTON, MA FROM MARCH 3-5, 2025. DETAILS OF THE COMPANY'S PARTICIPATION:

Atai Life Sciences N.V.

ATAI

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Atai Life Sciences N.V.

ATAI.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

ATAI